NCT00192283 - Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers | Biotech Hunter

Enrollment

2,903

Participants

Timeline

Start Date

September 30, 2000

Primary Completion Date

April 30, 2002

Study Completion Date

May 31, 2002

Conditions

Influenza

Interventions

BIOLOGICAL

CAIV-T

The total single-dose volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).

OTHER

Placebo

A single dose of placebo volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).

Trial Locations (1)

33520

Tampere University Medical School, Tampere